These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6953194)

  • 1. Preoperative determination of susceptibility to malignant hyperthermia.
    Carson JM; Van Sickels JE
    J Oral Maxillofac Surg; 1982 Jul; 40(7):432-5. PubMed ID: 6953194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis of susceptibility to malignant hyperthermia in children].
    Krivosic-Horber R; Adnet P; Krivosic I; Reyford H
    Arch Fr Pediatr; 1990; 47(6):421-4. PubMed ID: 2403268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of patients susceptible to malignant hyperthermia: A surgeon's perspective.
    Carlson KJ; Sun SA; Swan C; Koenig M; Derkay CS
    Int J Pediatr Otorhinolaryngol; 2022 Aug; 159():111187. PubMed ID: 35660936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant hyperthermia.
    Taiclet L
    Anesth Prog; 1985; 32(4):140-2. PubMed ID: 3865561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.
    O'Flynn RP; Shutack JG; Rosenberg H; Fletcher JE
    Anesthesiology; 1994 Jun; 80(6):1228-33. PubMed ID: 8010468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of otolaryngic patients susceptible to malignant hyperthermia without dantrolene.
    Derkay CS; Grundfast KM
    Otolaryngol Head Neck Surg; 1991 Nov; 105(5):680-6. PubMed ID: 1754251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.
    Halsall PJ; Cain PA; Ellis FR
    Br J Anaesth; 1979 Oct; 51(10):949-54. PubMed ID: 518796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant Hyperthermia Susceptibility and Fitness for Duty.
    Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
    Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dantrolene sodium in the management of patients at risk from malignant hyperthermia.
    Bronstein SL; Ryan DE; Solomons CC; Mahowald MC
    J Oral Surg; 1979 Oct; 37(10):719-24. PubMed ID: 289734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masseter muscle rigidity and malignant hyperthermia susceptibility.
    Rosenberg H; Fletcher JE
    Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Screening tests for malignant hyperthermia susceptibility].
    Krivosic-Horber R; Adnet P
    Ann Fr Anesth Reanim; 1989; 8(5):444-56. PubMed ID: 2560612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
    Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
    Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic effects on the variability of the halothane and caffeine muscle contracture tests.
    Urwyler A; Censier K; Kaufmann MA; Drewe J
    Anesthesiology; 1994 Jun; 80(6):1287-95. PubMed ID: 8010475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
    Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
    Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
    Allen GC; Rosenberg H; Fletcher JE
    Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
    Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility.
    Johannsen S; Klingler W; Schneiderbanger D; Heiderich S; Roewer N; Schuster F
    Acta Anaesthesiol Scand; 2013 Oct; 57(9):1161-6. PubMed ID: 23957432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant hyperthermia in the oral and maxillofacial surgery patient: an update.
    Patil PM
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Sep; 112(3):e1-7. PubMed ID: 21827956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.